Novavax (NVAX) Enterprise Value (2010 - 2026)

Novavax's Enterprise Value history runs 17 years deep, the most recent figure standing at -$562.0 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 23.17% year-over-year to -$562.0 million; the TTM figure through Mar 2026 stood at -$562.0 million (up 23.17% YoY), while the FY2025 annual figure was -$505.3 million, down 25.23% from the prior year.
• Enterprise Value was -$562.0 million for Q1 2026 at Novavax, down from -$505.3 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$10.3 million in Q2 2022 to a low of -$909.5 million in Q3 2024.
• Historically, Enterprise Value has averaged -$372.1 million across 5 years, with a median of -$403.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value surged 99.44% in 2022, then tumbled 5937.13% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$10.3 million in 2022, then declined by 1.17% to -$10.4 million in 2023, then sank by 3771.01% to -$403.5 million in 2024, then fell by 25.23% to -$505.3 million in 2025, then decreased by 11.22% to -$562.0 million in 2026.
• The last three Enterprise Value figures came in at -$562.0 million (Q1 2026), -$505.3 million (Q4 2025), and -$762.9 million (Q3 2025), per Business Quant data.